135 related articles for article (PubMed ID: 11313279)
1. Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin.
Doroshow JH; Synold TW; Somlo G; Akman SA; Gajewski E
Blood; 2001 May; 97(9):2839-45. PubMed ID: 11313279
[TBL] [Abstract][Full Text] [Related]
2. Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin.
Gajewski E; Gaur S; Akman SA; Matsumoto L; van Balgooy JN; Doroshow JH
Biochem Pharmacol; 2007 Jun; 73(12):1947-56. PubMed ID: 17445777
[TBL] [Abstract][Full Text] [Related]
3. DNA base modifications induced in isolated human chromatin by NADH dehydrogenase-catalyzed reduction of doxorubicin.
Akman SA; Doroshow JH; Burke TG; Dizdaroglu M
Biochemistry; 1992 Apr; 31(13):3500-6. PubMed ID: 1313297
[TBL] [Abstract][Full Text] [Related]
4. Oxidative DNA base damage in renal, hepatic, and pulmonary chromatin of rats after intraperitoneal injection of cobalt(II) acetate.
Kasprzak KS; Zastawny TH; North SL; Riggs CW; Diwan BA; Rice JM; Dizdaroglu M
Chem Res Toxicol; 1994; 7(3):329-35. PubMed ID: 8075364
[TBL] [Abstract][Full Text] [Related]
5. Facts about the artifacts in the measurement of oxidative DNA base damage by gas chromatography-mass spectrometry.
Dizdaroglu M
Free Radic Res; 1998 Dec; 29(6):551-63. PubMed ID: 10098459
[TBL] [Abstract][Full Text] [Related]
6. Oxidative modification of DNA bases in rat liver and lung during chemical carcinogenesis and aging.
Wang YJ; Ho YS; Lo MJ; Lin JK
Chem Biol Interact; 1995 Feb; 94(2):135-45. PubMed ID: 7828220
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
Holmes FA; Valero V; Walters RS; Theriault RL; Booser DJ; Gibbs H; Fraschini G; Buzdar AU; Willey J; Frye D; Asmar L; Hortobagyi GN
Ann Oncol; 1999 Apr; 10(4):403-11. PubMed ID: 10370782
[TBL] [Abstract][Full Text] [Related]
8. GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment.
Raiter A; Lipovetzki J; Lubin I; Yerushalmi R
BMC Cancer; 2020 Apr; 20(1):333. PubMed ID: 32306920
[TBL] [Abstract][Full Text] [Related]
9. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
[TBL] [Abstract][Full Text] [Related]
10. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
11. Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna-A Randomized, Cross-Over Clinical Study.
Hayslip J; Dressler EV; Weiss H; Taylor TJ; Chambers M; Noel T; Miriyala S; Keeney JT; Ren X; Sultana R; Vore M; Butterfield DA; St Clair D; Moscow JA
PLoS One; 2015; 10(4):e0124988. PubMed ID: 25909710
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
14. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
Gabra H; Cameron DA; Lee LE; Mackay J; Leonard RC
Br J Cancer; 1996 Dec; 74(12):2008-12. PubMed ID: 8980405
[TBL] [Abstract][Full Text] [Related]
15. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Batist G; Harris L; Azarnia N; Lee LW; Daza-Ramirez P
Anticancer Drugs; 2006 Jun; 17(5):587-95. PubMed ID: 16702817
[TBL] [Abstract][Full Text] [Related]
16. [Adriamycin (doxorubicin)].
Ogura M
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1331-8. PubMed ID: 11681238
[TBL] [Abstract][Full Text] [Related]
17. Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells.
Falcone A; Lencioni M; Brunetti I; Pfanner E; Allegrini G; Antonuzzo A; Andreuccetti M; Malvaldi G; Danesi R; Del Tacca M; Conte PF
Ann Oncol; 1997 Jun; 8(6):539-45. PubMed ID: 9261522
[TBL] [Abstract][Full Text] [Related]
18. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
19. DNA base modifications in chromatin of human cancerous tissues.
Olinski R; Zastawny T; Budzbon J; Skokowski J; Zegarski W; Dizdaroglu M
FEBS Lett; 1992 Sep; 309(2):193-8. PubMed ID: 1324197
[TBL] [Abstract][Full Text] [Related]
20. Butachlor induced dissipation of mitochondrial membrane potential, oxidative DNA damage and necrosis in human peripheral blood mononuclear cells.
Dwivedi S; Saquib Q; Al-Khedhairy AA; Musarrat J
Toxicology; 2012 Dec; 302(1):77-87. PubMed ID: 22884430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
